MarginsXMarginsX
Home › Markets › SGMOQ

Sangamo Therapeutics, Inc (SGMOQ)

SGMOQ is quoted over the counter, not listed on an exchange. Sangamo Therapeutics, Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 13, 2026
$0.1200
+9.1% on the day
1-year return
-73.3%
Market cap
$49.7M
Nano cap. From the Nov 13, 2026 close × 414.3M shares (10-Q cover page, May 11, 2026)
P/E and P/S
Net loss over the period · 1.4×
On trailing twelve months to March 31, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerSGMOQ, quoted over the counter
SEC CIK0001001233
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codeBiological Products, (No Diagnostic Substances)
Business addressRichmond, CA
Incorporated inDE

Warning signs

Cash runway
3.7 months
$27.6M cash at March 31, 2026
Share count, 1 year
+77.7%
2025-05-08 to 2026-05-11 · +141.1% over 3 years
Going-concern doubt
Yes
10-Q filed May 14, 2026
Insider net buying, 12 months
-$107K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These risks and uncertainties include, without limitation: There is substantial doubt about our ability to continue to operate as a going concern."
10-Q 2026-05-14
Cash and burn$27.6M cash; operating cash flow -$22.6M a quarter.Report 2026-03-31
Shares outstanding414,288,847 (2026-05-11); 233,166,972 a year earlier; 171,825,530 three years earlier.Cover page 2026-05-11
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-02-04
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-20
Delisting25-NSE filed25-NSE 2026-10-07
AuditorErnst & Young LLP, San Mateo, California, United States; changed auditors 1 time in 24 months8-K 4.01 2026-07-01
Late filings, 12 months1 NT noticeNT 10-Q 2026-08-17
Insider trades, 12 monthsBought $0, sold $107K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2026
2026-03-31
$1.4M-$31.0M-$19.3M$27.6MNo debt tags$34.6M10-Q 2026-05-14
Q4 2025
2025-12-31
$14.2M-$37.4M-$24.4M$20.9MNo debt tags$39.6M10-K 2026-03-30
Q3 2025
2025-09-30
$581K-$34.9M-$28.5M$29.6MNo debt tags$32.9M10-Q 2025-11-06
Q2 2025
2025-06-30
$18.3M-$20.0M-$18.2M$38.3MNo debt tags$81.7M10-Q 2025-08-07
Q1 2025
2025-03-31
$6.4M-$30.6M-$26.1M$25.2MNo debt tags$63.8M10-Q 2026-05-14
Q4 2024
2024-12-31
$7.6M-$23.4M-$3.4M$41.9MNo debt tags$57.8M10-K 2026-03-30
Q3 2024
2024-09-30
$49.4M$10.7M$11.8M$39.2MNo debt tags$52.3M10-Q 2025-11-06
Q2 2024
2024-06-30
$356K-$36.1M-$26.9M$27.8MNo debt tags$12.3M10-Q 2025-08-07

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-04
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-05-14
Latest current report8-K2026-10-27
Latest proxyDEF 14A2025-04-30

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier